BioVeda Capital
VC Fund
Singapore, Singapore
BioVeda Capital is a VC fund in Singapore focused on Health Care and Biotechnology. BioVeda is a Singapore based firm. They invest in companies in the healthcare sector with leading market positions, proprietary technologies, and outstanding scientific and management talent. They are a crucial business and scientific bridge between companies in the East and West, linking business and technology between two very diverse markets.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries BioVeda Capital invests in
Stages BioVeda Capital invests in
Countries BioVeda Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $6.7M–$34M
Investment Focus
Industry
- Health Care 3 (43%)
- Biotechnology 3 (43%)
- Medical 2 (29%)
- Fitness 1 (14%)
- Internet 1 (14%)
Stage
- Series B 5 (71%)
- Series A 2 (29%)
Country
- Singapore 3 (43%)
- United States 3 (43%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Damien Lim
General Partner
|
General Partner | Total investments: 1 | Find email | |
|
Damien Lim
General Partner & Founder
|
General Partner & Founder | Total investments: 0 | Find email | |
|
Zhi Yang
Founder & Partner
|
Founder & Partner | Total investments: 0 | Find email | |
Zhi Yang
Founder & Partner
|
Founder & Partner | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Sensely is a developer of avatar and chatbot-based platform designed to assist insurance plan members and patients. The company's platform leverages conversational interfaces and provides virtual assistant solutions to insurance companies, pharmaceutical clients, and hospital systems worldwide, enabling enterprises to converse with theirmembers in an entirely new way, combining the empathy of human conversation with the efficiency and scalability of the technology. | $8M / Series B / Feb 14, 2017 | ||
| From a modest start in 2013, when they had just three Fortune 500 clients, CXA has grown to become Asia’s leading Insurtech start-up - affirmed by over 600 clients and backed by a group of astute investors who understand the value and transformative potential of CXA’s groundbreaking platform.Employees are now able to proactively manage theirhealth by choosing the best-suited insurance, wellness and disease management offerings while employers are able to view aggregated health and claims analytics of their workforce to prioritise interventions that reduce costs and improve workplace health, productivity and employee engagement. | $8M / Series A / Jan 09, 2015 | ||
| ASLAN is an Asia enabled pharmaceutical company that develops novel medicines for global markets. | $22M / Series B / Oct 10, 2013 | ||
| Biolidics is a medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring. | $6.7M / Series B / Mar 13, 2013 | ||
| IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected withHepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc. | $27M / Series B / Jun 15, 2004 | ||
| IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected withHepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc. | Series A / Dec 09, 2002 | ||
| Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain. | $34.3M / Series B / Jan 10, 2002 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does BioVeda Capital invest in?
BioVeda Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BioVeda Capital's check size?
BioVeda Capital typically joins rounds of $6.7M–$34M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BioVeda Capital participates in.
How do I contact BioVeda Capital?
Public channels for BioVeda Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BioVeda Capital?
The team at BioVeda Capital includes Damien Lim (General Partner), Damien Lim (General Partner & Founder) and Zhi Yang (Founder & Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
